BRPI0715621A2 - Formulações galênicas de compostos orgânicos - Google Patents

Formulações galênicas de compostos orgânicos

Info

Publication number
BRPI0715621A2
BRPI0715621A2 BRPI0715621-9A2A BRPI0715621A BRPI0715621A2 BR PI0715621 A2 BRPI0715621 A2 BR PI0715621A2 BR PI0715621 A BRPI0715621 A BR PI0715621A BR PI0715621 A2 BRPI0715621 A2 BR PI0715621A2
Authority
BR
Brazil
Prior art keywords
organic compounds
galenic formulations
galenic
formulations
compounds
Prior art date
Application number
BRPI0715621-9A2A
Other languages
English (en)
Inventor
Begonia Carreno-Gomez
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0715621A2 publication Critical patent/BRPI0715621A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0715621-9A2A 2006-08-25 2007-08-21 Formulações galênicas de compostos orgânicos BRPI0715621A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119520A EP1891937A1 (en) 2006-08-25 2006-08-25 Galenic formulations of aliskiren
PCT/EP2007/058674 WO2008023016A2 (en) 2006-08-25 2007-08-21 Galenic formulations of aliskiren

Publications (1)

Publication Number Publication Date
BRPI0715621A2 true BRPI0715621A2 (pt) 2014-05-20

Family

ID=37560917

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715621-9A2A BRPI0715621A2 (pt) 2006-08-25 2007-08-21 Formulações galênicas de compostos orgânicos

Country Status (11)

Country Link
US (1) US20090280172A1 (pt)
EP (2) EP1891937A1 (pt)
JP (1) JP2010501524A (pt)
KR (1) KR20090043528A (pt)
CN (1) CN101505724A (pt)
AU (1) AU2007287549B2 (pt)
BR (1) BRPI0715621A2 (pt)
CA (1) CA2660138A1 (pt)
MX (1) MX2009002041A (pt)
RU (1) RU2009110452A (pt)
WO (1) WO2008023016A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205232A2 (en) * 2007-09-28 2010-07-14 Novartis Ag Galenical formulations of aliskiren
WO2009125432A2 (en) * 2008-04-11 2009-10-15 Lupin Limited Gas empowered expandable drug delivery systems
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010060199A1 (en) * 2008-11-25 2010-06-03 Merck Frosst Canada Ltd. Transdermally administered aliskiren
EP2429503A1 (en) * 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Pharmaceutical system for trans-membrane delivery
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
TWI625129B (zh) 2011-11-10 2018-06-01 歐米亞國際公司 新穎的經塗布控釋活性劑載體
EP3075376A1 (en) 2011-11-10 2016-10-05 Omya International AG New coated controlled release active agent carriers
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
WO2013165468A1 (en) * 2012-05-02 2013-11-07 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
WO2015099638A1 (en) 2013-12-23 2015-07-02 Colgate-Palmolive Company Tooth whitening oral care product
CN105828802B (zh) * 2013-12-23 2020-08-04 高露洁-棕榄公司 用于口腔使用的薄膜组合物
US10952959B2 (en) 2017-01-11 2021-03-23 Ferring B.V. Fast disintegrating pharmaceutical composition
CN112057629A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209067D0 (en) * 2002-04-20 2002-05-29 Microtherm Int Ltd Flexible vacuum insulation panel and method of manufacture
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion

Also Published As

Publication number Publication date
CA2660138A1 (en) 2008-02-28
US20090280172A1 (en) 2009-11-12
AU2007287549B2 (en) 2011-02-03
EP1891937A1 (en) 2008-02-27
JP2010501524A (ja) 2010-01-21
EP2056790A2 (en) 2009-05-13
MX2009002041A (es) 2009-03-06
RU2009110452A (ru) 2010-09-27
WO2008023016A2 (en) 2008-02-28
WO2008023016A3 (en) 2009-01-29
CN101505724A (zh) 2009-08-12
KR20090043528A (ko) 2009-05-06
AU2007287549A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
BRPI0715621A2 (pt) Formulações galênicas de compostos orgânicos
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
MA28490B1 (fr) Formulations galeniques de composes organiques
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
BRPI0718874A2 (pt) Compostos orgânicos
BRPI0817442A2 (pt) Formulações galênicas de composto orgânicos
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK2041139T3 (da) Farmaceutiske forbindelser
ES2527409T4 (es) Formulaciones de inhibidores de DPP IV
BRPI0718509A2 (pt) compostos orgânicos heterocíclicos
BRPI0821831A2 (pt) Compostos inseticidas
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0715712A2 (pt) Composição farmacêutica
ATE524477T1 (de) Aziridinylepothilonverbindungen
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
ATE463498T1 (de) Imidazo-verbindungen
BRPI0712902A2 (pt) compostos orgânicos
CR10562A (es) Nuevos derivados de piridazina
BRPI0814188A2 (pt) Formulações
BRPI0820677A2 (pt) Misturas de compostos pesticidas
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
CR9144A (es) Formulaciones de benzoxazoles sustituidos
DK2016067T3 (da) Insecticidforbindelser
BRPI1007452A2 (pt) formulações galênicas de compostos orgânicos

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES.

B08I Application fees: publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.